huberman retatrutide Lab Podcast on Amazon Music Huberman Lab - Listen here

The implications of commonalities and differences in insulin and GLP-1 secretions would provide deep insights into the coordination between blood glucose levels and the maintenance of body homeostasis

What the Data Shows The Phase 2 trial of retatrutide, published in the New England Journal of Medicine in 2023, enrolled 338 adults with obesity or overweight with a weight-related condition (5)

Each of these drugs is also marketed under a different name for the treatment of diabetes: semaglutide (Ozempic), tirzepatide (Mounjaro), and liraglutide (Victoza)

Many individuals notice: More significant weight loss Improved body composition Better physical endurance Greater motivation to stay consistent This is often when family members and friends begin noticing visible changes

Many users report significant improvement by weeks four through six

Other clear candidates include patients with BMI 35+ who have tried and failed multiple structured weight loss approaches, patients with obesity plus severe sleep apnea, and patients with a metabolic syndrome phenotype where reducing insulin resistance matters